The Company's lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. The ideal candidate combines scientific training with strong organizational and project management skills, enjoys working in a dynamic biotechnology environment, and is comfortable collaborating with scientists, technical development teams, and external partners.